of Epstein-Barr virus-encoded latent membrane protein 1 during
long-term human immunodeficiency virus infection: Reliable
markers for individual strain identification. J Infect Dis 179:240–
244.
Boyle MJ, Sewell WA, Sculley TB, Apolloni A, Turner JJ, Swanson CE,
Penny R, Cooper DA. 1991. Subtypes of Epstein-Barr virus in
human immunodeficiency virus-associated non-Hodgkin lymphoma. Blood 78:3004–3011.
Buck M, Cross S, Krauer K, Kienzle N, Sculley TB. 1999. A-type and B- type Epstein-Barr virus differ in their ability to spontaneously
enter the lytic cycle. J Gen Virol 80:441–445.
CDC. 1992. Revised classification system for HIV infection and
expanded surveillance case definition for AIDS among adolescents
and adults. Morb Mortal Wkly Rep 41:1–19.
Chabay P, De Matteo E, Merediz A, Preciado MV. 2004. High frequency
of Epstein Barr virus latent membrane protein-1 30 bp deletion in a
series of pediatric malignancies in Argentina. Arch Virol 149:1515 –
1526.
Chen ML, Tsai CN, Liang CL, Shu CH, Huang CR, Sulitzeanu D, Liu
ST, Chang YS. 1992. Cloning and characterization of the latent
membrane protein (LMP) of a specific Epstein-Barr virus variant
derived from the nasopharyngeal carcinoma in the Taiwanese
population. Oncogene 7:2131–2140.
Correa RM, Fellner MD, Alonio LV, Durand K, Teyssie AR, Picconi MA.
2004. Epstein-barr virus (EBV) in healthy carriers: Distribution of
genotypes and 30 bp deletion in latent membrane protein-1 (LMP-1)
oncogene. J Med Virol 73:583–588.
Edwards RH, Seillier-Moiseiwitsch F, Raab-Traub N. 1999. Signature
amino acid changes in latent membrane protein 1 distinguish
Epstein-Barr virus strains. Virology 261:79–95.
Fassone L, Cingolani A, Martini M, Migliaretti G, Oreste PL, Capello D,
Gloghini A, Vivenza D, Dolcetti R, Carbone A, Antinori A, Gaidano
G, Larocca LM. 2002. Characterization of Epstein-Barr virus
genotype in AIDS-related non-Hodgkin's lymphoma. AIDS Res
Hum Retroviruses 18:19–26.
Gratama JW, Ernberg I. 1995. Molecular epidemiology of Epstein-Barr
virus infection. Adv Cancer Res 67:197–255.
Gutierrez MI, Kingma DW, Sorbara L, Tran M, Raffeld M, Jaffe ES,
Magrath I, Bhatia K. 2000. Association of EBV strains, defined by
multiple loci analyses, in non-Hodgkin lymphomas and reactive
tissues from HIV positive and HIV negative patients. Leuk
Lymphoma 37:425–429.
Henderson S, Rowe M, Gregory C, Croom-Carter D, Wang F, Longnecker R, Kieff E, Rickinson A. 1991. Induction of bcl-2 expression
by Epstein-Barr virus latent membrane protein 1 protects infected
B cells from programmed cell death. Cell 65:1107–1115.
Hu LF, Zabarovsky ER, Chen F, Cao SL, Ernberg I, Klein G, Winberg G.
1991. Isolation and sequencing of the Epstein-Barr virus BNLF-1
gene (LMP1) from a Chinese nasopharyngeal carcinoma. J Gen
Virol 72:2399–2409.
Hu LF, Chen F, Zheng X, Ernberg I, Cao SL, Christensson B, Klein G,
Winberg G. 1993. Clonability and tumorigenicity of human
epithelial cells expressing the EBV encoded membrane protein
LMP1. Oncogene 8:1575–1583.
Kaye KM, Izumi KM, Kieff E. 1993. Epstein-Barr virus latent
membrane protein 1 is essential for B-lymphocyte growth transformation. Proc Natl Acad Sci U S A 90:9150–9154.
Kingma DW, Weiss WB, Jaffe ES, Kumar S, Frekko K, Raffeld M. 1996.
Epstein-Barr virus latent membrane protein-1 oncogene deletions:
Correlations with malignancy in Epstein-Barr virus-associated
lymphoproliferative disorders and malignant lymphomas. Blood
88:242–251.
Knecht H, Bachmann E, Joske DJ, Sahli R, Emery-Goodman A,
Casanova JL, Zilic M, Bachmann F, Odermatt BF. 1993. Molecular
analysis of the LMP (latent membrane protein) oncogene in
Hodgkin's disease. Leukemia 7:580–585.
Knecht H, Raphael M, McQuain C, Rothenberger S, Pihan G,
Camilleri-Broet S, Bachmann E, Kershaw GR, Ryan S, Kittler
EL, Quesenberry PJ, Schlaifer D, Woda BA, Brousset P. 1996.
Deletion variants within the NF-kappa B activation domain of
the LMP1 oncogene prevail in acquired immunodeficiency
syndrome-related large cell lymphomas and human immunodeficiency virus-negative atypical lymphoproliferations. Blood 87:876 –
881.
